Soleno Therapeutics (NASDAQ: SLNO) has officially launched VYKAT™ XR (diazoxide choline) extended-release tablets in the U.S. market, with first prescriptions already delivered to patients. The FDA-approved treatment, specifically designed for hyperphagia in Prader-Willi syndrome (PWS) patients aged four and older, received authorization on March 26, 2025.
VYKAT XR stands as the only FDA-approved treatment for hyperphagia, which is the primary cause of mortality in PWS patients. The company reports strong initial interest in the medication and has implemented Soleno ONE™, a comprehensive support program to facilitate access for patients, caregivers, and healthcare providers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.